Natco Pharma appoints TC Mallikarjuna as Vice President - QC at Kothur Pharma Division

Written by Ruchika Sharma Published On 2025-08-01T11:30:27+05:30 | Updated On 2 Aug 2025 2:52 PM IST

Natco Pharma appoints TC Mallikarjun as Vice President - QC at Kothur Pharma Division

Hyderabad: Natco Pharma has announced the appointment of T.C. Mallikarjuna as Vice President - QC at Pharma Division, Kothur of the Company.

T.C. Mallikarjuna has experience in the leading Indian Pharma Manufacturing Industries. He also has experience in handling regulatory Inspections like USFDA, MHRA, TGA, ANVISA, etc., and managing new products and exhibit validations. He was associated with Aurobindo Pharma Limited, Hyderabad, as Senior General Manager - Head QC before joining the Company.

The appointment comes amid a series of key leadership changes at Natco Pharma in recent months. In July, Dr Muddasaani Pulla Reddy, Executive Vice President - R & D and CH Srinivas, Senior Vice President - Demand & Supply superannuated from Natco Pharma. In addition, R. Sridhar Reddy – Senior Vice President – GCQA also resigned from the Company.

Earlier in June, Natco Pharma appointed Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda of the Company.

In May, the company named Dilip Manikchand Dhore as Vice President – Corporate Quality Assurance, and Amber Roy as Associate Vice President – Distribution. Additionally, Addagada Veeranarayana and Parupalli Sreenivasa Rao were appointed Associate Vice Presidents – Operations, while Kurada Venkata Maruti Ramchander was designated as Associate Vice President – Regulatory Affairs.

NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven company in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

natco pharmanatco pharma newsappointmentTC Mallikarjun

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751